Many peptide receptors are of pharmaceutical interest and there is thus a need for new ligands for such receptors. Unfortunately, peptides are not suitable as orally administrated drugs since they are associated with poor absorption, rapid metabolism and low sub-receptor selectivity. One approach that should allow identification of more drug-like ligands is to use the structural information of the endogenous ligand to develop peptidomimetic compounds. The main objective of the work described in this thesis was to convert angiotensin II (Ang II, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) to small drug-like compounds with retained bioactivity at the AT2 receptor. The study was performed step-wise via incorporation of well-defined secondary structure mimetics and repeated truncation of the peptide. Five scaffolds, comprising a benzene ring as a central element, suitable as a γ-turn or dipeptide mimetics were designed and synthesized. In order to decorate the scaffolds, a method of microwave-assisted alkoxycarbonylation was developed. After incorporation of the scaffolds into Ang II-related peptides or peptide fragments, the affinities for both the AT1 and the AT2 receptor were determined. In the first series of ligands, two tyrosine-related scaffolds were introduced as γ-turn mimetics in Ang II. All five pseudopeptides exhibited good affinities for the AT2 receptor. One compound was chosen for functional studies and was shown to act as an AT2 receptor agonist. After truncation of Ang II it was shown that C-terminal pentapeptide analogs were AT2 receptor selective agonists. A series of pseudopeptides comprising tyrosine-related scaffolds, derived from the pentapeptides, displayed high AT2 receptor affinities. Two compounds had agonistic effect at the AT2 receptor. This study revealed that the N-terminal part was of less importance while a C-terminal Ile residue was a key element for enhanced AT2 receptor affinity. In the final set of compounds, the peptide was truncated to tripeptide C-terminal fragments. After replacing His-Pro by a histidine-related scaffold small drug-like peptidomimetic compounds with nanomolar affinity for the AT2 receptor were identified.

Homotrimeric P2X3 and heteromeric P2X2/3 receptors are present in sensory ganglia and participate in pain perception. In order to develop pharmacological antagonists for these receptors, it is important to clarify which amino acid (AA) residues constitute the agonist binding pouch as well as to learn the stoichiometry of the receptor subunits forming a heteromeric receptor. We expressed the homomeric human (h)P2X3 receptor or its mutants in HEK293 cells and measured the ATP-induced responses by the whole-cell patch-clamp method. For the binding-site mutants, all conserved and some non-conserved AAs in the four nucleotide binding segments (NBSs) of the P2X3 subunit were sequentially replaced by alanine. Especially the positively charged AAs Lys and Arg appeared to be of critical importance for the agonist effects. We concluded that groups of AAs organized in NBSs rather than individual amino acids appear to be responsible for agonist binding at the P2X3 receptor. These NBSs are located at the interface of the three subunits forming a functional receptor. We were also interested to find out, whether two heteromeric receptors (P2X2/3 and P2X2/6), where P2X2 combines with two different partners, have an obligatory subunit stoichiometry of 1:2 or whether the subunit stoichiometry may be variable. For this purpose we used non-functional P2X2, P2X3 and P2X6 subunit-mutants to investigate the composition of heteromeric P2X2/3 and P2X2/6 receptors. The subunit stoichiometry of P2X2/3 and P2X2/6 was found to be 1:2 and 2:1, respectively. Thus, recognitions sites between P2X2 and its partners rather than random association may govern the subunit compositions of the receptor trimers.

Postmenopausal osteoporosis is a disease characterized by bone loss and increased risk of fracture, and represents a significant burden on the Canadian health care system. Current treatments lack the ability to simultaneously address the therapeutic needs for promoting bone formation and inhibiting resorption. Our approach employs a novel conjugate drug in which an anabolic agent (EP4 receptor agonist) is reversibly joined with an anti-resorptive agent (alendronate) through a linker. This allows the bone-targeting ability of alendronate to deliver the EP4 agonist to bone sites, thereby mitigating the side effects associated with systemic administration of the EP4 agonist. This study investigated the in vivo efficacy of this drug in a curative experiment to treat postmenopausal osteoporosis using an ovariectomized rat model. Results showed that conjugate treatment dose-dependently stimulated bone formation and restored ovariectomy-induced bone loss, and conjugation between alendronate and the EP4 agonist was crucial to the drug’s anabolic effect.

Postmenopausal osteoporosis is a disease characterized by bone loss and increased risk of fracture, and represents a significant burden on the Canadian health care system. Current treatments lack the ability to simultaneously address the therapeutic needs for promoting bone formation and inhibiting resorption. Our approach employs a novel conjugate drug in which an anabolic agent (EP4 receptor agonist) is reversibly joined with an anti-resorptive agent (alendronate) through a linker. This allows the bone-targeting ability of alendronate to deliver the EP4 agonist to bone sites, thereby mitigating the side effects associated with systemic administration of the EP4 agonist. This study investigated the in vivo efficacy of this drug in a curative experiment to treat postmenopausal osteoporosis using an ovariectomized rat model. Results showed that conjugate treatment dose-dependently stimulated bone formation and restored ovariectomy-induced bone loss, and conjugation between alendronate and the EP4 agonist was crucial to the drug’s anabolic effect.

It has been observed that confusion exists in literature concerning the meaning and use of the term efficacy. Confusion is worsened by the use of the term as a general term describing agonist activity. The meaning of the terms intrinsic activity, efficacy and intrinsic efficacy as used in theoretical models of drug action was investigated. The classical occupation model, the two-state model, the ternary complex model (including conformational change and ideas surrounding G-proteins) and the operational model were studied in order to understand the historical and current usage of these terms. Although efficacy estimates are often reported as a molecular property, it was shown that agonist activity is tissue dependent and cannot be fully portrayed by an efficacy estimate. It was found that efficacy has a different definition in each model. This is not always recognized in literature. It was suggested that the term efficacy should only be used in the context of a specific model / Thesis (M.Sc. (Pharmacology))--North-West University, Potchefstroom Campus, 2007.

Influenza virus infects the human population worldwide and causes acute respiratory disease. Currently, the primary strategy for preventing influenza is seasonal vaccination which is capable of providing protection in most populations. However, seasonal vaccines are less efficacious to immunize the elderly and poorly induce cross-protective immunity against the reassorted pandemic virus in the recipients. Neuraminidase (NA) inhibitors have also been widely utilized to limit disease outcome. The currently used NA inhibitors, nonetheless, generate the drug-resistant progeny viruses; moreover, they are unable to directly target the host immune responses which cause immunopathology in severe cases. Therefore, new strategies that provide more effective immunogenicity, cross-protection and therapies against influenza infection must be developed. In this thesis, the adjuvanticity of CpG oligodeoxynucleotide (ODN), type I interferon (IFN) and Complete Freund’s adjuvant (CFA) when coadministered with seasonal influenza vaccines in ferrets is presented. It has been found that the adjuvanted vaccines are efficacious to induce neutralizing antibody responses. Several common and distinguished signaling pathways leading to dendritic cell (DC) maturation and B cell activation have been discovered from their adjuvanticity. Furthermore, it was determined that seasonal H1N1 prior infection more effectively induces cross-protection against the newly emerged 2009 pandemic H1N1 (H1N1pdm) virus in ferrets and mice than the seasonal vaccines. The prior infection-induced cross-reactive but non-neutralizing antibodies are capable of providing substantial protection in the H1N1pdm infected mice when CD8 T cells are absent. Lastly, function of different vaccine adjuvants for controlling H1N1pdm infection in mice has been investigated. Unlike other adjuvants, CFA is capable of protecting the mice from infection through enhancement of Treg cell suppressive molecules galectin-1 and CTLA-4 which downregulated DC costimulation and effector T cell responses. Overall, this thesis has provided novel mechanistic insights for developing protective strategies against influenza infection.

The dopamine D2 receptor exists in vitro in two states of agonist affinity: a high-affinity state mediating dopamine’s physiological effects, and a physiologically-inert low-affinity state. Our primary goal was to determine the in vivo relevance of this two-affinity-state model for the agonist PET radiotracer [11C]-(+)-PHNO, developed for measurement of the D2 high-affinity state. Our second goal was to characterize the regional D2 versus D3 pharmacology of [3H]-(+)-PHNO binding and assess its utility for measuring drug occupancy at both receptor subtypes. Using ex vivo dual-radiotracer experiments in conscious rats, we showed that, contrary to the two-affinity-state model, the binding of [11C]-(+)-PHNO and the antagonist [3H]-raclopride were indistinguishably inhibited by D2 partial agonist (aripiprazole), indirect agonist (amphetamine) and full agonist ((-)-NPA) pretreatment. Furthermore, ex vivo [11C]-(+)-PHNO binding was unaffected by treatments that increase in vitro high-affinity state density (chronic amphetamine, ethanol-withdrawal), whereas unilateral 6-OHDA lesion, which increases total D2 receptor expression, similarly increased the ex vivo binding of [11C]-(+)-PHNO and [3H]-raclopride. These results do not support the in vivo validity of the two-affinity-state model, suggesting instead a single receptor state for [11C]-(+)-PHNO and [3H]-raclopride in conscious rat. Importantly, we also demonstrated that the increased amphetamine-sensitivity of the agonist radiotracers [11C]-(+)-PHNO and [11C]-(-)-NPA, commonly seen in isoflurane-anaesthetized animals and cited as evidence for the two-affinity-state model, is due to the confounding effects of anaesthesia. Using in vitro and ex vivo autoradiography in rat and the D3 receptor-selective drug SB277011, we found that [3H]-(+)-PHNO binding in striatum and cerebellum lobes 9 and 10 was due exclusively to D2 and D3 receptor binding, respectively, but in other extra-striatal regions to a mix of the two receptor subtypes. Surprisingly, the D3 contribution to [3H]-(+)-PHNO binding was greater ex vivo than in vitro. Also surprising, several antipsychotic drugs, at doses producing 80% D2 occupancy, produced insignificant (olanzapine, risperidone, haloperidol) or small (clozapine, ~35%) D3 occupancy, despite similarly occupying both receptor subtypes in vitro. These data reveal a significant discrepancy between in vitro and ex vivo measures of dopamine receptor binding and suggest that the D3 occupancy is not necessary for the therapeutic effect of antispychotic drugs.

Influenza virus infects the human population worldwide and causes acute respiratory disease. Currently, the primary strategy for preventing influenza is seasonal vaccination which is capable of providing protection in most populations. However, seasonal vaccines are less efficacious to immunize the elderly and poorly induce cross-protective immunity against the reassorted pandemic virus in the recipients. Neuraminidase (NA) inhibitors have also been widely utilized to limit disease outcome. The currently used NA inhibitors, nonetheless, generate the drug-resistant progeny viruses; moreover, they are unable to directly target the host immune responses which cause immunopathology in severe cases. Therefore, new strategies that provide more effective immunogenicity, cross-protection and therapies against influenza infection must be developed. In this thesis, the adjuvanticity of CpG oligodeoxynucleotide (ODN), type I interferon (IFN) and Complete Freund’s adjuvant (CFA) when coadministered with seasonal influenza vaccines in ferrets is presented. It has been found that the adjuvanted vaccines are efficacious to induce neutralizing antibody responses. Several common and distinguished signaling pathways leading to dendritic cell (DC) maturation and B cell activation have been discovered from their adjuvanticity. Furthermore, it was determined that seasonal H1N1 prior infection more effectively induces cross-protection against the newly emerged 2009 pandemic H1N1 (H1N1pdm) virus in ferrets and mice than the seasonal vaccines. The prior infection-induced cross-reactive but non-neutralizing antibodies are capable of providing substantial protection in the H1N1pdm infected mice when CD8 T cells are absent. Lastly, function of different vaccine adjuvants for controlling H1N1pdm infection in mice has been investigated. Unlike other adjuvants, CFA is capable of protecting the mice from infection through enhancement of Treg cell suppressive molecules galectin-1 and CTLA-4 which downregulated DC costimulation and effector T cell responses. Overall, this thesis has provided novel mechanistic insights for developing protective strategies against influenza infection.

Premenstrual depressive symptoms and mood swings affect 3-8% of women in fertile age. The female hormones are believed to be the cause. Progesterone is well studied, but estrogen is not, and either are other causes such as intimate partner violence and chronic stress. The aim in this thesis was to investigate the influence of hormones as well as psychological aspects on the most common problems among women seeking care for premenstrual symptoms. In a cross-sectional study, four groups of women were included: ongoing users of oral contraceptives, with or without adverse mood symptoms and previous users, with or without experience of adverse mood. Depression and anxiety were significantly more common in both groups with reported adverse mood, in comparison with their control groups with no adverse mood. Self-reported PMS was significantly more common in those women who reported adverse mood, however, there was no difference in prospectively defined PMS or PMDD between the two groups of previous users. In a RCT with 25 women completing the study, GnRH treatment were tested in combination with two different HRT add-back doses of estradiol, in combination with progesterone and placebo. The higher dose of estrogen 1.5 mg in combination with progesterone induced significantly more pronounced symptoms than in combination with placebo. The lower dose, 0.5 mg gave less symptom recurrence in combination with progesterone. Exposure to violence was investigated among PMDD patients, healthy controls and gynecological patients. Among the participating women, gynecological patients, reported physical and/or emotional abuse significantly more often than did PMDD patients, as well as healthy controls. Chronic stress was investigated with diurnal cortisol, and low-dose dexamethasone test.  There was no difference in diurnal secretion of cortisol between PMDD patients and controls. No difference in the degree of dexamethasone suppression was found between PMDD patients and controls. According to the results from these studies, the main symptom provoking factor in women with PMDD appears to be the estradiol and progesterone fluctuations across the menstrual cycle, whereas chronic stress and intimate partner violence appears to be less relevant.

A inseminação artificial em tempo fixo (IATF), juntamente com a inseminação artificial pós-cervical (IAPC), permite uma redução expressiva da mão de obra e uma melhor utilização dos machos geneticamente superiores. O objetivo deste estudo foi avaliar a eficiência do eCG associado agonista de GnRH (buserelina) ou apenas buserelina para indução e sincronização da ovulação em porcas desmamadas e submetidos a apenas uma IATF. Um total de 495 femeas suínas desmamadas foram utilizadas, cuja detecção de estro foi realizada uma vez ao dia (07:30). As fêmeas foram divididas em três tratamentos: Controle (n = 165) - a primeira IA foi realizada no início do estro (0 h) e repetida a cada 24 h, posteriormente, durante o estro; Tratamento 2: eCG + GnRH (n = 165) – femeas receberam uma injeção intramuscular de 600 UI de eCG após o desmame, e uma injeção intramuscular de buserelina (10 μg) 86-89 h após a administração de eCG; Tratamento 3: GnRH - fêmeas receberam uma injeção intramuscular de buserelina (10 μg) 86-89 h após o desmame. Nos três grupos era realizada a exposição ao macho no dia seguinte ao desmame uma vez ao dia, e aquelas fêmeas que demostrassem estro eram retiradas dos protocolos de IATF. Os grupos tratados receberam uma única IA, 118-120 h após o desmame (30-33 h após a buserelina). A IAPC contou com doses homospérmicas (1,5 x 109 células de espermáticas/50 ml) que foram utilizadas nas femeas em todos os três tratamentos. Não houve diferenças entre os tratamentos quanto ao número de femeas em estro até o terceiro dia (P>0,05). O intervalo entre o desmame e a ovulação foi significativamente maior (P< 0,05) no grupo controle (141,5 ± 1,58 h) comparativamente aos tratamentos eCG+GnRH (133,3 ± 1,60 h) e GnRH (135,9 ± 1,57 h). As femeas do tratamento eCG+GnRH ovularam em média antes (P<0,05) em relação ao grupo GnRH (44,5 ± 1,74 vs 48,2 ± 1,73 h). A taxa de parto foi superior (P<0,05) no grupo de controle, comparativamente aos tratamentos eCG + GnRH e GnRH, mas não houve diferença (P>0,05) em leitões nascidos totais entre os tratamentos. O uso do GnRH, com ou sem a administração prévia de eCG, antecipa a ovulação nas fêmeas suínas desmamadas. Nas fêmeas tratadas com eCG+GnRH ou GnRH, há em maior percentual de fêmeas inseminadas fora do momento ideal, em relação à ovulação, o que pode prejudicar o desempenho reprodutivo, sendo necessários ajustes no momento de aplicação dos hormônios ou no momento da inseminação para estudos subsequentes. / Fixed-time artificial insemination (FTAI) together with post-cervical artificial insemination (PCAI), allows an expressive reduction in labor requirements and a wider use of higher indexing boars. The aim of this study was to evaluate the efficiency of eCG agonist of GnRH (buserelin) or just buserelin for induction and synchronization of ovulation in weaned sows and submitted to FTAI .A total of 495 weaned sows whose estrus detection was performed once daily (07:30 A.M), starting a day after weaning. The sows were allocated into three treatment groups: Control (n=165) – the first AI was performed at estrus onset (0 h) and repeated every 24 h thereafter during estrus; Treatment 2: eCG + GnRH (n=165) – sows received an intramuscular injection of 600 UI eCG after weaning, and an intramuscular injection of buserelin (10 μg) 86-89 h after eCG administration; Treatment 3: GnRH - sows received an intramuscular injection of buserelina (10 μg) 86-89 h after weaning. . In the three groups it was performed boar exposure in the following day to weaning once a day, and those sows that demonstrated oestrus were removed from FTAI protocols. Treated groups received a single AI, 118-120 h after weaning (30-33 h after buserelin). PCAI with homospermic doses (1.5 x 109 total of sperm cells/50 ml) were respectively performed in sows in all treatment group. There were no differences (P> 0,05) in number of sows that showed oestrus until the third day between treatments. The interval between weaning and ovulation was significantly higher (P< 0,05) in the control group (141,5 ± 1,58 h) comparatively the treatments eCG+GnRH (133,3 ± 1,60 h) and GnRH (135,9 ± 1,57 h). Sows of treatment eCG+GnRH ovulated earlier (P< 0,05) comparing to the GnRH group (44,5 ± 1,74 vs 48,2 ± 1,73 h). Higher (P<0,05) farrowing rate in control group comparatively to treatments eCG+GnRH e GnRH was observed, but there were no differences (P> 0,05) in total piglets born between treatments. Use of GnRH, with or without previous administration of eCG anticipates ovulation in sows weaned, in the sows treated with eCG + GnRH or GnRH, there is a greater percentage of females inseminated outside the ideal time, with respect to ovulation, it can harm the reproductive performance, with necessary adjustments at the time of application hormones or at the time of insemination for subsequent studies.